Latest news with #Weblink
Yahoo
2 days ago
- Business
- Yahoo
Gene Therapy Collaboration and Licensing Deals Report and Directory 2025: Explore the Financials Behind 787 Gene Therapy Licensing Deals from 2016-2025
The Gene Therapy Collaboration and Licencing Deals report features 787 deals with financial terms and SEC contracts. Explore trends in R&D partnerships, commercialization strategies, and IP structures. Ideal for benchmarking deal terms, assessing opportunities, and streamlining due diligence in the gene therapy space. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2025" report has been added to report contains a comprehensive listing of 787 gene therapy deals announced since 2016, including financial terms where available, and links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Gene Therapy Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the gene therapy deals entered into by the world's leading biopharma revised and updated, the report provides details of gene therapy deals from 2016 to report provides a detailed understanding and analysis of how and why companies enter gene therapy deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of report includes collaboration, development, research and licensing initial chapters of this report provide an orientation of gene therapy dealmaking. Chapter 1 introduces the report, while Chapter 2 provides an overview of the trends in gene therapy dealmaking since 2016. Chapter 3 offers a summary of the leading gene therapy deals since 2016, listed by headline value. Chapter 4 lists the top 25 most active companies in gene therapy dealmaking, with summaries and comprehensive listings of deals. Chapter 5 and Chapter 6 offer detailed reviews of gene therapy deals and partnering deals announced since Jan 2016, focusing on contract documents in the public domain and specific gene therapy technologies report also includes numerous tables and figures that illustrate the trends and activities in gene therapy deal making since 2016. In addition, a comprehensive deal directory is provided, organized by company A-Z, deal type, and therapeutic target. Each deal title links via Weblink to an online version of the deal record and, where available, the contract document, providing easy access to each contract document on Therapy Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse gene therapy collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeGene Therapy Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of gene therapy trends and structure of deals entered into by leading biopharma companies Therapy Collaboration and Licensing Deals includes: Trends in gene therapy dealmaking in the biopharma industry Directory of gene therapy deal records covering pharmaceutical and biotechnology The leading gene therapy deals by value Most active gene therapy licensing dealmakers Gene Therapy Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered:Chapter 1 - IntroductionChapter 2 - Trends in gene therapy dealmaking2.1. Introduction2.2. Gene therapy deals over the years2.3. Most active gene therapy dealmakers2.4. Gene therapy deals by deal type2.5. Gene therapy deals by therapy area2.6. Gene therapy deals by industry sector2.7. Deal terms for gene therapy deals2.7.1 Gene therapy deals headline values2.7.2 Gene therapy deal upfront payments2.7.3 Gene therapy deal milestone payments2.7.4 Gene therapy royalty ratesChapter 3 - Leading gene therapy deals3.1. Introduction3.2. Top gene therapy deals by valueChapter 4 - Most active gene therapy dealmakers4.1. Introduction4.2. Most active gene therapy dealmakers4.3. Most active gene therapy deals company profilesChapter 5 - Gene therapy contracts dealmaking directory5.1. Introduction5.2. Gene therapy contracts dealmaking directoryChapter 6 - Gene therapy dealmaking by technology typeDeal directory Deal directory - Gene therapy deals by company A-Z Deal directory - Gene therapy deals by deal type Deal directory - Gene therapy deals by therapy area For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
2 days ago
- Business
- Yahoo
Companion Diagnostic Collaboration and Licensing Deals Analysis Report and Directory 2025: Updated Biopharma Diagnostic Deals from 2010 Through 2025 Detailed
The report analyzes 545 global deals, including licensing terms, financials, and SEC contract documents. With data from top biopharma collaborations, it provides insights into dealmaking trends, partner strategies, and benchmarking tools for diagnostics commercialization. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Companion Diagnostic Collaboration and Licensing Deals 2010-2025" report has been added to report contains a comprehensive listing of 545 companion diagnostic deals announced since 2010 including financial terms where available, and links to online deal records of actual companion diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the companion diagnostic deals entered into by the world's leading biopharma revised and updated, the report provides details of companion diagnostic deals from 2010 to report provides a detailed understanding and analysis of how and why companies enter companion diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of report includes collaboration, development, research, and licensing initial chapters of this report provide an orientation of companion diagnostic dealmaking. Chapter 1 provides an introduction to the report. Chapter 2 gives an overview of trends in companion diagnostic dealmaking since 2010, while Chapter 3 lists leading deals by headline value. Chapter 4 lists the top 25 most active companies in dealmaking. Chapters 5 and 6 offer a detailed review of companion diagnostic deals signed and announced since Jan 2010, highlighting technologies and public contract report also includes numerous tables and figures that illustrate the trends and activities in companion diagnostic deal-making since addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2010 Browse companion diagnostic collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeCompanion Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of companion diagnostic trends and structure of deals entered into by leading biopharma companies Diagnostic Collaboration and Licensing Deals includes: Trends in companion diagnostic dealmaking in the biopharma industry Directory of companion diagnostic deal records covering pharmaceutical and biotechnology The leading companion diagnostic deals by value Most active companion diagnostic licensing dealmakers Companion Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered:Chapter 1 - IntroductionChapter 2 - Trends in companion diagnostic dealmaking2.1. Introduction2.2. Companion diagnostic deals over the years2.3. Most active companion diagnostic dealmakers2.4. Companion diagnostic deals by deal type2.5. Companion diagnostic deals by therapy area2.6. Companion diagnostic deals by industry sector2.7. Deal terms for companion diagnostic deals2.7.1 Companion diagnostic deals headline values2.7.2 Companion diagnostic deal upfront payments2.7.3 Companion diagnostic deal milestone payments2.7.4 Companion diagnostic royalty ratesChapter 3 - Leading companion diagnostic deals3.1. Introduction3.2. Top companion diagnostic deals by valueChapter 4 - Most active companion diagnostic dealmakers4.1. Introduction4.2. Most active companion diagnostic dealmakers4.3. Most active companion diagnostic deals company profilesChapter 5 - Companion diagnostic contracts dealmaking directory5.1. Introduction5.2. Companion diagnostic contracts dealmaking directoryChapter 6 - Companion diagnostic dealmaking by technology typeDeal directory Deal directory - Companion diagnostic deals by company A-Z Deal directory - Companion diagnostic deals by deal type Deal directory - Companion diagnostic deals by therapy area For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Monoclonal Antibody Collaboration and Licensing Deals Directory 2025: 670 Monoclonal Antibody Licensing Deals from 2019-2025 Analyzed
The 2025 report on Monoclonal Antibody Collaboration & Licensing Deals details 670 transactions from 2019-2025. Covering R&D, licensing, and commercialization deals, it includes financial terms, deal structures, and SEC contract links. A vital tool for benchmarking, deal-making insights, and partner due diligence in the biopharma antibody space. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Monoclonal Antibody Collaboration and Licensing Deals 2019-2025" report has been added to Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the monoclonal antibody deals entered into by the world's leading biopharma revised and updated, the report provides details of monoclonal antibody deals from 2019 to report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of report includes collaboration, development, research and licensing report contains a comprehensive listing of 670 monoclonal antibody deals announced since 2019 including financial terms where available including links to online deal records of actual monoclonal antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of monoclonal antibody dealmaking. Chapters 1 to 6 offer a comprehensive introduction and a detailed overview of trends, leading deals, active companies, and technology-specific deals since 2019. Key insights and contract documents are provided where available, to deepen understanding of the sector's landscape. The report also includes numerous tables and figures that illustrate the trends and activities in monoclonal antibody dealmaking since report also includes numerous table and figures that illustrate the trends and activities in monoclonal antibody deal making since addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Antibody Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2019 Browse monoclonal antibody collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeMonoclonal Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of monoclonal antibody trends and structure of deals entered into by leading biopharma companies Antibody Collaboration and Licensing Deals includes: Trends in monoclonal antibody dealmaking in the biopharma industry Directory of monoclonal antibody deal records covering pharmaceutical and biotechnology The leading monoclonal antibody deals by value Most active monoclonal antibody licensing dealmakers Monoclonal Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered:Chapter 1 - IntroductionChapter 2 - Trends in monoclonal antibody dealmaking2.1. Introduction2.2. Monoclonal antibody deals over the years2.3. Most active monoclonal antibody dealmakers2.4. Monoclonal antibody deals by deal type2.5. Monoclonal antibody deals by therapy area2.6. Monoclonal antibody deals by industry sector2.7. Deal terms for monoclonal antibody deals2.7.1 Monoclonal antibody deals headline values2.7.2 Monoclonal antibody deal upfront payments2.7.3 Monoclonal antibody deal milestone payments2.7.4 Monoclonal antibody royalty ratesChapter 3 - Leading monoclonal antibody deals3.1. Introduction3.2. Top monoclonal antibody deals by valueChapter 4 - Most active monoclonal antibody dealmakers4.1. Introduction4.2. Most active monoclonal antibody dealmakers4.3. Most active monoclonal antibody deals company profilesChapter 5 - Monoclonal antibody contracts dealmaking directory5.1. Introduction5.2. Monoclonal antibody contracts dealmaking directoryChapter 6 - Monoclonal antibody dealmaking by technology typeDeal directory Deal directory - Monoclonal antibody deals by company A-Z Deal directory - Monoclonal antibody deals by deal type Deal directory - Monoclonal antibody deals by therapy area For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- Business
- Yahoo
Cardiovascular Collaboration and Licensing Deals Report 2025: A Detailed Analysis of 589 Cardiovascular Deals from 2016 to 2025 - Key Players, Payments, and SEC Contracts Explored
The Cardiovascular Collaboration and Licensing Deals report details 589 biopharma agreements, analyzing financials, royalties, and deal structures. It includes links to actual contract documents, trends by therapeutic focus and technology, and insights into the most active dealmakers, offering critical benchmarking for future negotiations. Dublin, June 12, 2025 (GLOBE NEWSWIRE) -- The "Cardiovascular Collaboration and Licensing Deals 2016-2025" report has been added to Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cardiovascular deals entered into by the worlds leading biopharma revised and updated, the report provides details of 589 cardiovascular deals from 2016 to report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of cardiovascular dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in cardiovascular 3 covers the financial deal terms for deals signed in the cardiovascular field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty 4 provides a review of the top 25 most active biopharma companies in cardiovascular dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances 5 provides a comprehensive and detailed review of cardiovascular deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on 6 provides a comprehensive directory of cardiovascular deals listed by therapeutic report also includes numerous table and figures that illustrate the trends and activities in cardiovascular deal making since addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse cardiovascular collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Report ScopeCardiovascular Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cardiovascular trends and structure of deals entered into by leading biopharma companies Collaboration and Licensing Deals includes: Trends in cardiovascular dealmaking in the biopharma industry Overview of collaboration and licensing deal structure Directory of cardiovascular deal records covering pharmaceutical and biotechnology The leading cardiovascular deals by value Most active cardiovascular licensing dealmakers In Cardiovascular Collaboration and Licensing Deals, the available deals are listed by: Company A-Z Headline value Therapeutic area Technology type Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Chapter 1 - IntroductionChapter 2 - Trends in cardiovascular dealmaking2.1. Introduction2.2. Cardiovascular partnering over the years2.3. Cardiovascular partnering by deal type2.4. Cardiovascular partnering by industry sector2.5. Cardiovascular partnering by stage of development2.6. Cardiovascular partnering by technology type2.7. Cardiovascular partnering by therapeutic indicationChapter 3 - Financial deal terms for cardiovascular partnering3.1. Introduction3.2. Disclosed financials terms for cardiovascular partnering3.3. Cardiovascular partnering headline values3.4. Cardiovascular deal upfront payments3.5. Cardiovascular deal milestone payments3.6. Cardiovascular royalty ratesChapter 4 - Leading cardiovascular deals and dealmakers4.1. Introduction4.2. Most active in cardiovascular partnering4.3. List of most active dealmakers in cardiovascular4.4. Top cardiovascular deals by valueChapter 5 - Cardiovascular contract document directory5.1. Introduction5.2. Cardiovascular partnering deals where contract document availableChapter 6 - Cardiovascular dealmaking by therapeutic target6.1. Introduction6.2. Deals by cardiovascular therapeutic targetDeal directory Deal directory - Cardiovascular deals by company A-Z 2016 to 2025 Deal directory - Cardiovascular deals by technology type 2016 to 2025 For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
Molecular Diagnostics Collaboration and Licensing Agreements Analysis Report 2025 with Directory of 759 Deals Signed Since 2016 - Upfront, Milestone, Royalties Financial Terms
The report also includes numerous table and figures that illustrate the trends and activities in molecular diagnostics deal making since 2016. In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand. Dublin, May 23, 2025 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics Collaboration and Licensing Deals 2016-2025" report has been added to revised and updated, the report provides details of molecular diagnostics deals from 2016 to report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. Molecular Diagnostics Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the molecular diagnostics deals entered into by the world's leading biopharma companies. The report includes collaboration, development, research and licensing report contains a comprehensive listing of 759 molecular diagnostics deals announced since 2016 including financial terms where available including links to online deal records of actual molecular diagnostics partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their initial chapters of this report provide an orientation of molecular diagnostics 1 provides an introduction to the 2 provides an overview of the trends in molecular diagnostics dealmaking since 3 provides an overview of the leading molecular diagnostics deals since 2016. Deals are listed by headline 4 provides a comprehensive listing of the top 25 most active companies in molecular diagnostics dealmaking with a brief summary followed by a comprehensive listing of molecular diagnostics deals, as well as contract documents available in the public 5 provides a comprehensive and detailed review of molecular diagnostics deals signed and announced since Jan 2016, where a contract document is available in the public 6 provides a comprehensive and detailed review of molecular diagnostics partnering deals signed and announced since Jan 2016. The chapter is organized by specific molecular diagnostics technology type in Diagnostics Collaboration and Licensing Deals provides the reader with the following key benefits: Understand deal trends since 2016 Browse molecular diagnostics collaboration and licensing deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, deal type and therapy area Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time Molecular Diagnostics Collaboration and Licensing Deals includes: Trends in molecular diagnostics dealmaking in the biopharma industry Directory of molecular diagnostics deal records covering pharmaceutical and biotechnology The leading molecular diagnostics deals by value Most active molecular diagnostics licensing dealmakers Analyzing contract agreements allows due diligence of: What are the precise rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? Key Topics Covered: Executive SummaryChapter 1 - IntroductionChapter 2 - Trends in molecular diagnostics dealmaking2.1. Introduction2.2. Molecular diagnostics deals over the years2.3. Most active molecular diagnostics dealmakers2.4. Molecular diagnostics deals by deal type2.5. Molecular diagnostics deals by therapy area2.6. Molecular diagnostics deals by industry sector2.7. Deal terms for molecular diagnostics deals2.7.1 Molecular diagnostics deals headline values2.7.2 Molecular diagnostics deal upfront payments2.7.3 Molecular diagnostics deal milestone payments2.7.4 Molecular diagnostics royalty ratesChapter 3 - Leading molecular diagnostics deals3.1. Introduction3.2. Top molecular diagnostics deals by valueChapter 4 - Most active molecular diagnostics dealmakers4.1. Introduction4.2. Most active molecular diagnostics dealmakers4.3. Most active molecular diagnostics deals company profilesChapter 5 - Molecular diagnostics contracts dealmaking directory5.1. Introduction5.2. Molecular diagnostics contracts dealmaking directoryChapter 6 - Molecular diagnostics dealmaking by technology typeDeal directory Deal directory - Molecular diagnostics deals by company A-Z Deal directory - Molecular diagnostics deals by deal type Deal directory - Molecular diagnostics deals by therapy area Deal type definitions For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
